KRAS G12D
KRAS G12D is a point mutation in the KRAS gene that substitutes aspartate for Glycine at codon 12.
KRAS G12D is a point mutation in the KRAS gene that substitutes aspartate for Glycine at codon 12. Glycine-12 sits in the P-loop that cradles the γ-phosphate of bound GTP, and the larger aspartate side chain obstructs the arginine finger that GTPase-activating proteins insert to catalyze hydrolysis. The mutant therefore retains residual intrinsic GTPase activity but is effectively deaf to GAP stimulation, so it accumulates in the GTP-bound state and signals continuously through the RAF–MEK–ERK cascade, the PI3K/AKT/mTOR pathway, and RAL guanine nucleotide exchange factors, driving proliferation and survival independently of upstream receptor input.
It is among the most prevalent oncogenic drivers in human Cancer. In pancreatic ductal adenocarcinoma, where KRAS is mutated in over 90% of Tumors, G12D is the single most common variant at roughly 35–45% of cases; it is also frequent in colorectal cancer and appears in lung adenocarcinoma, though there KRAS G12C predominates.
G12D was long considered undruggable, and the reason is specific rather than general: picomolar affinity for GTP rules out competitive nucleotide inhibitors, and the covalent strategy that yielded the first approved KRAS drugs depends on a reactive cysteine that G12C provides and G12D does not. Progress has come from non-covalent inhibitors that exploit the aspartate itself, from RAS(ON) compounds that act on the active GTP-bound state through a cyclophilin A complex rather than on the inactive state, and from targeted protein degradation. In parallel, the mutant peptide is being pursued as a public neoantigen through T cell receptor–engineered cell Therapy and vaccines, since a recurrent single substitution presented on a shared HLA allele is the same target for many patients. Adaptive reactivation of ERK Signaling is the recurring obstacle to all of the direct approaches, which is why combinations with upstream or downstream inhibitors are under active study.
Where the papers sit
9 papers from the last 6 months study KRAS G12D directly · updated from PubMed 13 Nov 2026
Study type 0 clinical trials · 4 human data · 4 preclinical · 1 unclassified
Themes one subject · 1 paradigm shift
Those 9 are all about one subject.
-
KRAS G12D Therapeutics
Selective inhibitors and CRBN-based degraders are driving efforts to treat KRAS G12D cancers, especially metastatic pancreatic cancer. Clinical testing is moving toward allele-specific therapy, while immunotherapy and combinations aim to extend response. Resistance recurs through ANXA1-mediated metabolic reprogramming and MEK/ERK-linked unfolded protein response, with glutamine restriction and nimotuzumab offering reversal strategies. Mutation-sensitive ctDNA assays may support treatment selection and monitoring.
Acquired KRAS G12D-inhibitor resistance can be therapeutically reversed rather than treated as an irreversible failure of allele-specific inhibition
The pancreatic ductal adenocarcinoma study of HRS-4642 resistance and glutamine restriction found that a glutamine-restricted diet reversed resistance through disruption of ANXA1-driven glutamine metabolism and produced remission with prolonged survival 42561948Aug, while the pancreatic cancer study of HRS-4642-resistant cell lines, patient-derived xenografts, and clinical samples found that nimotuzumab reversed resistance by blocking MEK/ERK-mediated unfolded-protein-response reactivation 42303056Jun. Together, these distinct metabolic and signaling interventions show that resistance to KRAS G12D inhibition is not necessarily a terminal loss of drug sensitivity; it can be restored by targeting adaptations that arise during treatment.
Papers
The 9 papers from the last 6 months that study KRAS G12D directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
KRAS G12D Therapeutics (9)
- Discovery of INCB161734: A Selective Inhibitor of the KRAS G12D Mutant. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018629
- Rat sarcoma inhibitors in and beyond gynecologic malignancies. Current opinion in obstetrics & gynecology · 24 Oct 2026 PMID 42924896
- Hitting KRAS G12D without the gut punch: Can immunotherapy make it last? Cancer cell · 12 Oct 2026 PMID 42863460
- Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720481
- One-pot SP-EXPAR-integrated CRISPR/Cas14a assay for highly specific and versatile detection of ctDNA mutations in lung cancer patients. Analytical methods : advancing methods and applications · 24 Aug 2026 PMID 42635115
- The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. Journal of hematology & oncology · 8 Aug 2026 PMID 42571010
- Glutamine-restricted diets restore sensitivity to KRASG12D inhibitor through the reversal of ANXA1 mediated metabolic reprogramming. Cell reports. Medicine · 6 Aug 2026 PMID 42561948
- Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK/ERK-mediated unfolded protein response in pancreatic cancer. Cancer letters · 16 Jun 2026 PMID 42303056
- The KRASG12D Inhibitor Pipeline Grows. Cancer discovery · 16 Jun 2026 PMID 42299111
By study type
Human data, design not indexed (4)
- Hitting KRAS G12D without the gut punch: Can immunotherapy make it last? Cancer cell · 12 Oct 2026 PMID 42863460
- One-pot SP-EXPAR-integrated CRISPR/Cas14a assay for highly specific and versatile detection of ctDNA mutations in lung cancer patients. Analytical methods : advancing methods and applications · 24 Aug 2026 PMID 42635115
- The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. Journal of hematology & oncology · 8 Aug 2026 PMID 42571010
- The KRASG12D Inhibitor Pipeline Grows. Cancer discovery · 16 Jun 2026 PMID 42299111
Preclinical: animal, cell and lab studies (4)
- Discovery of INCB161734: A Selective Inhibitor of the KRAS G12D Mutant. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018629
- Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720481
- Glutamine-restricted diets restore sensitivity to KRASG12D inhibitor through the reversal of ANXA1 mediated metabolic reprogramming. Cell reports. Medicine · 6 Aug 2026 PMID 42561948
- Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK/ERK-mediated unfolded protein response in pancreatic cancer. Cancer letters · 16 Jun 2026 PMID 42303056
Unclassified: not yet indexed with MeSH (1)
- Rat sarcoma inhibitors in and beyond gynecologic malignancies. Current opinion in obstetrics & gynecology · 24 Oct 2026 PMID 42924896
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-08-08. Last written: 2026-09-12 by GPT. Corrections: 2026-08-08 by GPT. Drafted by language models from published abstracts; not medical advice.